Impact of the Metabolic Syndrome on Angiographic and Clinical Events After Coronary Intervention Using Bare-Metal or Sirolimus-Eluting Stents

American Journal of Cardiology

Volumn 100, Issue 9, 2007, Pages 1347-1352

  Hoffmann, Rainer ^a   Stellbrink, Ekaterina ^a   Schröder, Jörg ^a   Grawe, Armin ^a   Vogel, Gunter ^a   Blindt, Rüdiger ^a   Kelm, Malte ^a   Radke, Peter W ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; METAL; RAPAMYCIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; STENTS;

EID: 35348847924     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.021     Document Type: Article

References (22)

1. Marroquin O.C., Kip K.E., Kelley D.E., Johnson B.D., Shaw L.J., Bairey Merz C.N., Sharaf B.L., Pepine C.J., Sopko G., and Reis S.E. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 109 (2004) 714-721
2. Lean M.E., Han T.S., and Morrison C.E. Waist circumference as a measure for indicating need for weight management. BMJ 311 (1995) 158-161
3. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 107 (2003) 391-397
4. Grundy S.M., Cleeman J.I., and Daniels S.R. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
5. Gilbert J., Raboud J., and Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 27 (2004) 990-994
6. Abizaid A., Kornowski R., Mintz G.S., Hong M.K., Abizaid A.S., Mehran R., Pichard A.D., Kent K.M., Satler L.F., Wu H., et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 32 (1998) 584-589
7. West N.E.J., Ruygrok P.N., Disco C.M.C., Webster M.W.I., Lindeboom W.K., O'Neill W.W., Mercado N.F., and Serruys P.W. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 109 (2004) 867-873
8. Takagi T., Yoshida K., Akasaka T., Kaji S., Kawamoto T., Honda Y., Yamamuro A., Hozumi T., and Moioka S. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients. J Am Coll Cardiol 36 (2002) 731-738
9. Hong S.J., Kim M.H., Ahn T.H., Ahn Y.K., Bae J.H., Shim W.J., Ro Y.M., and Lim D.S. Multiple predictors of coronary restenosis after drug-eluting stent implantation in diabetic patients. Heart 92 (2006) 1119-1124
10. Moussa I., Leon M.B., and Baim D.S. Impact of sirolimus eluting stents on outcome in diabetic patients. A SIRIUS (Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Coronary Artery Lesions) substudy. Circulation 109 (2004) 2273-2278
11. Scheen A.J., Warze'e F., and Legrand V.M.G. Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 25 (2004) 2167-2168
12. Lemos P.A., Serruys P.W., and van Domburg R.T. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world.". The Rapamycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
13. Dibra A., Kastrati A., Mehilli J., Pache J., Schuhlen H., von Beckerath N., Ulm K., Wessely R., Dirschinger J., Schomig A., and ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
14. Piatti P.M., Di Mario C., Monti L., Fragasso G., Sgura F., Caumo A., Setola E., Lucotti P., Galluccio E., Ronchi C., et al. Association of insulin resistance, hyperleptinemia and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 108 (2003) 2074-2081
15. Radke P.W., Voswinkel M., Reith M., Kaiser A., Haager P.K., Hanrath P., and Hoffmann R. Relation of fasting insulin plasma levels to restenosis after elective coronary stent implantation in patients without diabetes mellitus. Am J Cardiol 93 (2004) 639-641
16. Takagi T., Akasaka T., Yamamuro A., Honda Y., Hozumi T., Morioka S., and Yoshida K. Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation: intravascular ultrasound studies. J Diabetes Complications 16 (2002) 50-55
17. Muhlestein J.B., Anderson J.L., Horne B.D., Lavasani F., Allen Maycock C.A., Bair T.L., Pearson R.R., Carlquist J.F., and Intermountain Heart Collaborative Study Group. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 146 (2003) 351-358
18. 1c to rate of MACEs in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol 92 (2003) 1282-1286
19. Iribarren C., Go A.S., Husson G., Sidney S., Fair J.M., Quertermous T., Hlatky M.A., and Fortmann S.P. Metabolic syndrome and early-onset coronary artery disease. J Am Coll Cardiol 48 (2006) 1800-1807
20. Rana J.S., Monraats P.S., Zwinderman A.H., de Maat M.P.M., Kastelein J.J.P., Doevendans P.A.F., de Winter R.J., Tio R.A., Frants R.R., van der Laarse A., et al. Metabolic syndrome and risk of restenosis in patients undergoing percutaneous coronary intervention. Diabetes Care 28 (2005) 873-877
21. Freeman D.J., Norrie J., Caslake M.J., Gaw A., Ford I., Lowe G.D., O'Reilly D.S., Packard C.J., and Sattar N. West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51 (2002) 1596-1600
22. Han T.S., Williams K., Sattar N., Hunt K.J., Lean M.E., and Haffner S.M. Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res 10 (2002) 923-931